A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: Depot versus oral

Journal of Clinical Psychiatry

Volumn 69, Issue 10, 2008, Pages 1548-1556

  Patel, Maxine X ^a   De Zoysa, Nicole ^a   Bernadt, Morris ^a   David, Anthony S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTITUDE TO HEALTH; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH BELIEF; HUMAN; INTROSPECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERSUASIVE COMMUNICATION; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STRUCTURED INTERVIEW;

EID: 54949134839     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1004     Document Type: Article

References (54)

1. Patel MX, David AS. Medication adherence: predictive factors and enhancement strategies. Psychiatry 2007;6(9):357-361
2. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
3. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia: economic and clinical issues. Pharmacoeconomics 2000;18:106-124
4. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909
5. Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653-1664
6. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-108
7. Hogarty GE, Schooler NR, Ulrich R, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979;36(12):1283-1294
8. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651
9. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(suppl 16):14-17
10. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder. BMJ 2006;333:224-227
11. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14(2):105-122
12. Young JL, Spitz RT, Hillbrand M, et al. Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments and prospects. J Am Acad Psychiatry Law 1999;27(3):426-444
13. Patel MX, David AS. Why aren't depots prescribed more often, and what can be done about it? Advances in Psychiatric Treatment 2005;11:203-213
14. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992;53:426-433
15. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-773
16. Walburn J, Gray R, Gournay K, et al. A systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-307
17. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003;33:83-89
18. Patel MX, De Zoysa N, Baker D, et al. Depot antipsychotic medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs 2005;12:237-244
19. Patel MX, De Zoysa N, Bernadt M, et al. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing [published online ahead of print June 26, 2008]. J Psychopharmacol.doi: 10.1177/0269881108092124
20. Rogers A, Pilgrim D. Service users' views of psychiatric treatments. Sociol Health Illn 1993;15(5):612-631
21. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004;65(7):932-939
22. Weiden P, Rapkin B, Zygmunt A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995;46(10):1049-1054
23. Tunnicliffe S, Harrison G, Standen PJ. Factors affecting compliance with depot injection treatment in the community. Soc Psychiatry Psychiatr Epidemiol 1992 Oct;27(5):230-233
24. Office for National Statistics. The Census of England and Wales. Available at: http://www.statistics.gov.uk/census2001. Accessed June 30, 2008.
25. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992
26. Weiden P, Rapkin B, Mott T, et al. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20(2):297-310
27. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-183
28. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24
29. Patel MX, de Zoysa N, Bernadt M, et al. Voluntary outpatients and coercions: depot versus oral antipsychotics. Schizophr Bull 2007;33:452
30. Gardner W, Hoge SK, Bennett N, et al. Two scales for measuring patients' perceptions for coercion during mental hospital admission. Behav Sci Law 1993;11(3):307-321
31. Page AC, Bennett KS, Carter O, et al. The Blood-Injection Symptom Scale (BISS): assessing a structure of phobic symptoms elected by blood and injections. Behav Res Ther 1997;35(5):457-464
32. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
33. Kemp R, David A. Insight and compliance. In: Blackwell B, ed. Treatment Compliance and the Therapeutic Alliance in Serious Mental Illness. Amsterdam, The Netherlands: Harwood Academic Publishers; 1997:61-84
34. Sanz M, Constable G, Lopez-Ibor I, et al. A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol Med 1998;28:437-446
35. Chouinard G, Ross-Chouinard A, Annable L, et al. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233
36. Priebe S, Huxley P, Knight S, et al. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry 1999;45(1):7-12
37. Frances A, Pincus HA. The Global Assessment of Functioning scale (GAF). In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association;1994
38. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64(11):1308-1315
39. Van Putten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187-190
40. Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients' perspective. Aust N Z J Psychiatry 2002;36:633-641
41. Freudenreich O, Cather C, Evins AE, et al. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004;65(10):1372-1376
42. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005;62:717-724
43. Farabee D, Shen H, Sanchez S. Program-level predictors of antipsychotic medication adherence among parolees. Int J Offender Ther Comp Criminol 2004 Oct;48(5):561-571
44. McPhillps M, Sensky T. Coercion, adherence or collaboration? Influences on compliance with medication. In: Wykes T, Tarrier N, Lewis S, eds. Outcome and Innovation in Psychological Treatment of Schizophrenia. Chichester, England: John Wiley & Sons; 1998:161-177
45. Hepburn T, Page AC. Effects of images about fear and disgust upon responses to blood-injury phobic people. Behav Ther 1999;30:63-77
46. David AS. Insight and psychosis. Br J Psychiatry 1990;156:798-808
47. Hughes I, Hill B, Budd R. Compliance with antipsychotic medication: from theory to practice. J Ment Health 1997;6:473-489
48. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(suppl 21):25-30
49. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002;288(22):2868-2879
50. Nosé M, Barbui C, Gray R, et al. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003;183:197-206
51. Donohoe G, Owens N, O'Donnell C, et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001;16(5):293-298
52. Rettenbacher MA, Hofer A, Eder U, et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry 2004;65:1211-1218
53. Mutsatsa SH, Joyce EM, Hutton SB, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand 2003;108:439-446
54. Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005;353:487-497